Recombinant SARS-CoV-2 Spike-Prot B.1.617.2 (HEK)

Name: Recombinant SARS-CoV-2 Spike-Prot B.1.617.2 (HEK)
Availability: InStock

Recombinant SARS-CoV-2 Spike-Prot B.1.617.2 (HEK)

Alternative names:

SARS-CoV-2 Delta variant

Data and images
Specifications

Product data and images for Recombinant SARS-CoV-2 Spike-Prot B.1.617.2 (HEK)

Figures

Figure 1

**Cell-based spike protein binding assay.**
Schematic overview illustrating how our biotinylated spike proteins can be applied to analyze binding to ACE2-expressing cells.

Figure 1

Cell-based spike protein binding assay.

Schematic overview illustrating how our biotinylated spike proteins can be applied to analyze binding to ACE2-expressing cells.

Figure 2

**Results of the cell-based binding assay using biotinylated Recombinant SARS-CoV-2 Spike-Prot B.1.617.2 (HEK).**
ACE2-expressing cells (Vero E6 cells) were incubated with biotinylated SARS-CoV-2 spike monomer of the wild-type, Wuhan variant (Recombinant SARS-CoV-2 Spike-Prot (HEK)-Biotin) and the SARS-CoV-2 variant B.1.617.2, Delta (Recombinant SARS-CoV-2 Spike-Prot B.1.617.2 (HEK)-Biotin).
Different protein concentrations were used, and ACE2-bound spike protein was subsequently detected by fluorescent staining with streptavidin-PE. Quantification of stained cells at different protein concentrations illustrates that Miltenyi Biotec's recombinant spike monomers are biologically functional and show a titratable, high-affinity binding to cell surface ACE2.

Figure 2

Results of the cell-based binding assay using biotinylated Recombinant SARS-CoV-2 Spike-Prot B.1.617.2 (HEK).

ACE2-expressing cells (Vero E6 cells) were incubated with biotinylated SARS-CoV-2 spike monomer of the wild-type, Wuhan variant (Recombinant SARS-CoV-2 Spike-Prot (HEK)-Biotin) and the SARS-CoV-2 variant B.1.617.2, Delta (Recombinant SARS-CoV-2 Spike-Prot B.1.617.2 (HEK)-Biotin).

Different protein concentrations were used, and ACE2-bound spike protein was subsequently detected by fluorescent staining with streptavidin-PE. Quantification of stained cells at different protein concentrations illustrates that Miltenyi Biotec's recombinant spike monomers are biologically functional and show a titratable, high-affinity binding to cell surface ACE2.

Figure 3

**SDS-PAGE of biotinylated Recombinant SARS-CoV-2 Spike-Prot B.1.617.2 (HEK)**
under reduced (R) and non-reduced (NR) conditions.

Figure 3

SDS-PAGE of biotinylated Recombinant SARS-CoV-2 Spike-Prot B.1.617.2 (HEK)

under reduced (R) and non-reduced (NR) conditions.

Specifications for Recombinant SARS-CoV-2 Spike-Prot B.1.617.2 (HEK)

Overview

The SARS-CoV-2 spike glycoprotein (S) mediates the entry of the virus into target cells via its interaction with the angiotensin-converting enzyme 2 (ACE2) receptor, thereby initiating the infection. It forms a homotrimeric structure on the surface of the SARS-CoV-2 virus and represents the major target for diagnostic and therapeutic agents. The ectodomain of the S glycoprotein comprises the N-terminal S1 subunit, including the receptor binding domain (RBD) and the C-terminal S2 subunit. The ectodomain spans from aa12 to aa1213 followed by a transmembrane helix beginning at aa1214–aa1234. The C-terminus of the native protein is formed by a cytoplasmic domain spanning aa1235–aa1273.

The SARS-CoV-2 mutant strain B.1.617.2, also known as Delta variant, was first identified during the Covid-19 pandemic in India in late 2020. Due to increased transmissibility it spread rapidly around the globe. The B.1.617.2 lineage is defined by two amino acid deletions Δ156–157 and 8 amino acid substitutions T19R, G142D, R158G, L452R, T478K, D614G, P681R, and D950N occurring in the spike protein. Among them, the L452R mutation is suspected to confer increased affinity of the spike protein to the ACE2 receptor and may decrease recognition of the B.1.617.2 lineage by the immune system.

The Recombinant SARS-CoV-2 Spike-Prot B.1.617.2 (HEK) protein covers the ectodomain of the viral surface protein including amino acids V16 to K1211. It was engineered to contain the stabilizing proline substitutions at position K986P and V987P. The native sequence of the Furin cleavage site (RRAR at residues 682–685) was substituted by GSAG to further increase recombinant protein stability.

In addition, the SARS-CoV-2 Spike-Prot B.1.617.2 (HEK) protein contains the amino acid deletions Δ156–157 and the amino acid substitutions T19R, G142D, R158G, L452R, T478K, D614G, P681R, and D950N. The protein is extended at its C-terminus with a His-tag and an AviTag™. Recombinant SARS-CoV-2 Spike-Prot B.1.617.2 (HEK)-Biotin is specifically biotinylated at a single site, preserving full functionality of the protein.

Alternative names

SARS-CoV-2 Delta variant

Data and images